Results 31 to 40 of about 101,617 (297)
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
Фармация и фармакология (Пятигорск), 2023 Modern requirements for the treatment of type 2 diabetes mellitus (DM2) include not only achieving a glycemic control, but also reducing the risk of developing cardiovascular complications.
D. V. Kurkin +9 more
doaj +1 more source
Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors [PDF]
, 2023 To investigate the risk of hyperkalaemia in new users of sodium–glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes mellitus (T2DM).
Tsang, Christopher Tze Wei +13 more
core +3 more sources
3D-QSAR-based pharmacophore determination and design of novel DPP-4 inhibitors [PDF]
Scripta Medica, 2022 Background/Aim: Therapy of diabetes mellitus type 2 includes drugs that act as inhibitors of dipeptidyl peptidase 4 (DPP-4) enzyme. Several DPP-4 inhibitors are marketed today and although they have favourable safety profile and tolerability, they show ...
Rogić Sanja, Gagić Žarko
doaj +1 more source
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS [PDF]
, 2016 Diabetes mellitus (DM) is a chronic disease which caused around 1.5 million deaths in 2012. Type 2 diabetes mellitus (T2DM) accounts for 90% of DM worldwide. The prevalence of T2DM is increasing due to obesity.
Kristin, Erna
core +1 more source
SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review [PDF]
, 2020 The prevalence of diabetes and its associated complications is increasing throughout the decades. Promising diabetes medications were introduced to the market including GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors aiming to target these ...
Christopher El Mouhayyar +4 more
core +1 more source
Journal of Research in Medical Sciences, 2022 Background: COVID-19 is responsible for the latest pandemic. Dipeptidyl peptidase-4 (DPP-4) is one of the cellular receptors of interest for coronavirus. The aim of this study was to assess the roles of DPP-4 inhibitors in prognosis of COVID-19 infection
Mohammad Sadidi +5 more
doaj +1 more source
Journal of Enzyme Inhibition and Medicinal Chemistry, 2018 Dipeptidyl peptidase 4 (DPP-4) inhibitors are used for the treatment of type-2 diabetes mellitus. Various synthetic inhibitors have been developed to date, and plants containing natural DPP-4 inhibitors have also been identified.
Eisuke Kato +2 more
doaj +1 more source
Organic solar cells based on acceptor-functionalized diketopyrrolopyrrole derivatives [PDF]
, 2015 This work was supported by the EPSRC (grants EP/E036244 and EP/I00343X).The synthesis and characterization of three solution processable diketopyrrolopyrrole (DPP) derivatives featuring acceptor units attached to the core by alkyne linker units is ...
Rotello, Vince +5 more
core +1 more source
Scientific Reports, 2018 The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings.
Lana C. Pinto +4 more
doaj +1 more source
Frontiers in Pharmacology, 2017 Diabetes mellitus has been demonstrated to be closely associated with osteoporosis. Accordingly, hypoglycemic therapy is considered effective in treating metabolic bone disease.
Yinqiu Yang +4 more
doaj +1 more source